ARA-290, also called cibinetide, is a synthetic 11-amino-acid peptide derived from a non-blood-building region of erythropoietin (EPO). It has been studied for its effects on inflammation, small-nerve-fibre repair and neuropathic pain. ARA-290 is not approved by the FDA or Thai FDA for any condition; it is a research-stage peptide that, where clinically appropriate, may be prescribed off-label and compounded by a licensed pharmacy partner under medical supervision at Menscape Clinic in Bangkok.
/)
Medically reviewed by Dr. Tuksaorn Suriyakan (Ping), Anti-Aging & Regenerative Medicine Physician
8 years of experience
Our solutions for Immune & Wellness
Indications evaluated in research, listed in order of current evidence weight. Suitability is determined case-by-case.
ARA-290 (cibinetide) is a short synthetic peptide based on the tissue-protective domain of erythropoietin, the hormone that normally signals red-blood-cell production. Unlike EPO itself, ARA-290 was engineered to keep the tissue-protective and anti-inflammatory signalling while avoiding the blood-thickening, red-cell-stimulating effect, which is why it is described as a non-erythropoietic peptide. It has been investigated mainly for neuropathic pain and small-nerve-fibre repair in conditions such as sarcoidosis-associated neuropathy and diabetic neuropathy. ARA-290 remains a research-stage molecule: it has completed several Phase 2 trials but is not approved as a medicine anywhere, and the human evidence base is still early.
/)
In laboratory and clinical research, ARA-290 is reported to act on the innate repair receptor, a receptor complex involving the beta-common (CD131) and EPO-receptor subunits that becomes active in injured or inflamed tissue. Through this pathway it has been studied for reducing local inflammation and supporting nerve-fibre survival and regrowth. Separate research suggests ARA-290 may also blunt signalling at the TRPV1 pain channel, which could contribute to its studied analgesic effects. These mechanisms are drawn from preclinical work and early human trials; they describe how the peptide is believed to act, not a confirmed clinical outcome.
/)
In trials, ARA-290 has been explored in adults with small-fibre neuropathy, including people with sarcoidosis-associated nerve damage and those with type 2 diabetes and neuropathic symptoms. At Menscape Clinic in Bangkok, any discussion of ARA-290 is individual and physician-led. It is not a first-line therapy and is not suitable for everyone; a doctor will review your medical history, current medications and goals, and will usually prioritise approved, evidence-based options before considering a research-stage peptide. It is not intended for people seeking a quick fix or a substitute for established care.
/)
Where a Menscape physician judges it clinically appropriate, ARA-290 may be prescribed off-label and compounded by a licensed pharmacy partner, then administered as a small daily subcutaneous (under-the-skin) injection, mirroring the dosing format used in published trials. Use is always under medical supervision with informed consent, baseline assessment and follow-up. Because human data are limited and ARA-290 is unapproved, the clinic frames any course as a carefully monitored trial of therapy rather than a proven treatment, and will stop if it is not appropriate or not helping.
/)
Every ARA-290 (Cibinetide) protocol starts with a full medical consultation and history review.
Prescriptions are filled by a licensed compounding pharmacy partner, not over-the-counter.
Follow-up consultations every four to six weeks to assess response and safety.
We frame ARA-290 (Cibinetide) as a research-stage option and prescribe only when clinically appropriate.
ARA-290 (cibinetide) is not approved by the US FDA or the Thai FDA for any medical condition. It has received FDA Orphan Drug and Fast Track designations for neuropathic pain in sarcoidosis, but these support investigation and are not the same as approval. Where appropriate, it may be prescribed off-label and compounded by a licensed pharmacy partner under a doctor's supervision.
In the Phase 2 trials reported so far, ARA-290 was generally well tolerated over short courses, but the total number of people studied is small and long-term safety is not established. Because it is research-stage and unapproved, its full risk profile is not fully known. Any use at Menscape is under medical supervision, with screening, monitoring and informed consent.
It has been studied mainly for neuropathic (nerve-related) pain and small-nerve-fibre repair, particularly in sarcoidosis-associated neuropathy and diabetic small-fibre neuropathy. Trials have also looked at markers of inflammation and nerve-fibre density. These are areas of active research, not confirmed approved uses.
ARA-290 is derived from a protective part of the erythropoietin (EPO) molecule but is engineered not to stimulate red-blood-cell production. The aim is to keep EPO's studied tissue-protective and anti-inflammatory signalling while avoiding the blood-thickening and cardiovascular risks associated with EPO. This distinction is one reason it has been researched as a separate, non-erythropoietic peptide.
In clinical studies, ARA-290 was given as a once-daily subcutaneous injection over short courses. If a Menscape physician considers it appropriate, it would be compounded by a licensed pharmacy partner and used in a similar supervised format, with baseline assessment and follow-up. Dosing is individualised by your doctor and is not something to self-manage.
We strongly advise against it. Products sold online as ARA-290 are often labelled research use only, are unregulated, and may differ in purity, identity or sterility from what the label claims. For a research-stage injectable peptide, that carries real safety risk. At Menscape Clinic in Bangkok, any decision involves a physician assessment, a licensed compounding partner and ongoing medical oversight.
/)
Dr. Tuksaorn (Dr. Ping) is an anti-aging and regenerative medicine physician with over 8 years of experience, focused on evidence-based wellness and personalized health programs that combine modern medical science with individualized care.
/)
/)
/)
/)
/)